Targeting ADAMS and ERBBs in lung cancer

被引：37

作者：

Hynes, Nancy E. ^{[1
]}

Schlange, Thomas ^{[1
]}

机构：

[1] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland

来源：

CANCER CELL | 2006年 / 10卷 / 01期

关键词：

D O I：

10.1016/j.ccr.2006.06.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aberrant ERBB receptor activity contributes to the development of many human cancers. Receptor overexpression, kinase domain (KD) mutations, and autocrine ligand production contribute to ERBB activation in human tumors. ERBB-targeted tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are used in cancer treatment; however, clinical hurdles, including patient selection and TKI resistance, need to be overcome in order to optimize therapy. This minireview will discuss recent findings on possible mechanisms leading to ERBB-targeted therapy resistance and potential means to overcome them.

引用

页码：7 / 11

页数：5

共 60 条

[1] Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy [J].

Asakura, M ;

Kitakaze, M ;

Takashima, S ;

Liao, Y ;

Ishikura, F ;

Yoshinaka, T ;

Ohmoto, H ;

Node, K ;

Yoshino, K ;

Ishiguro, H ;

Asanuma, H ;

Sanada, S ;

Matsumura, Y ;

Takeda, H ;

Beppu, S ;

Tada, M ;

Hori, M ;

Higashiyama, S .

NATURE MEDICINE, 2002, 8 (01) :35-40

[2] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].

Baselga, J ;

Arteaga, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459

[3] Where next for gefitinib in patients with lung cancer? [J].

Blackhall, Fiona ;

Ranson, Malcolm ;

Thatcher, Nick .

LANCET ONCOLOGY, 2006, 7 (06) :499-507

[4] Adams: Key components in EGFR signalling and development [J].

Blobel, CP .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (01) :32-43

[5] TACE is required for the activation of the EGFR by TGF-α in tumors [J].

Borrell-Pagès, M ;

Rojo, F ;

Albanell, J ;

Baselga, J ;

Arribas, J .

EMBO JOURNAL, 2003, 22 (05) :1114-1124

[6] HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients [J].

Cappuzzo, F ;

Toschi, L ;

Domenichini, I ;

Bartolini, S ;

Ceresoli, GL ;

Rossi, E ;

Ludovini, V ;

Cancellieri, A ;

Magrini, E ;

Bemis, L ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Hirsch, FR ;

Varella-Garcia, M .

BRITISH JOURNAL OF CANCER, 2005, 93 (12) :1334-1340

[7] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].

Cappuzzo, F ;

Bemis, L ;

Varella-Garcia, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621

[8] Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients [J].

Cappuzzo, F ;

Varella-Garcia, M ;

Shigematsu, H ;

Domenichini, I ;

Bartolini, S ;

Ceresoli, GL ;

Rossi, E ;

Ludovini, V ;

Gregorc, V ;

Toschi, L ;

Franklin, WA ;

Crino, L ;

Gazdar, AF ;

Bunn, RA ;

Hirsch, FR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5007-5018

[9] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].

Cappuzzo, F ;

Hirsch, FR ;

Rossi, E ;

Bartolini, S ;

Ceresoli, GL ;

Bemis, L ;

Haney, J ;

Witta, S ;

Danenberg, K ;

Domenichini, I ;

Ludovini, V ;

Magrini, E ;

Gregorc, V ;

Doglioni, C ;

Sidoni, A ;

Tonato, M ;

Franklin, WA ;

Crino, L ;

Bunn, PA ;

Varella-Garcia, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655

[10] Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab [J].

Cho, HS ;

Mason, K ;

Ramyar, KX ;

Stanley, AM ;

Gabelli, SB ;

Denney, DW ;

Leahy, DJ .

NATURE, 2003, 421 (6924) :756-760

← 1 2 3 4 5 6 →